Management of acute HCV infection in the era of direct-acting antiviral therapy
- PMID: 29773899
- DOI: 10.1038/s41575-018-0026-5
Management of acute HCV infection in the era of direct-acting antiviral therapy
Abstract
The management of acute HCV infection has not been standardized following the availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial uncertainty exists regarding the optimal treatment regimen and duration. Despite the lack of direct evidence, the 2016 American Association for the Study of Liver Diseases (AASLD)-Infectious Diseases Society of America (IDSA) guidelines supported "the same regimens for acute HCV as recommended for chronic HCV infection … owing to high efficacy and safety", whereas the 2016 European Association for the Study of the Liver (EASL) guidelines recommended sofosbuvir-ledipasvir, sofosbuvir-velpatasvir or sofosbuvir plus daclatasvir for 8 weeks in acute HCV infection, with a longer duration of 12 weeks recommended for those infected with HIV and/or baseline HCV RNA levels >1,000,000 IU/ml. This Review outlines the epidemiology, natural history and diagnosis of acute HCV infection and provides contemporary information on DAAs for acute and recent HCV infection. The Review also discusses the 2016 AASLD-IDSA and EASL recommendations for acute HCV infection management in light of available evidence and highlights key differences in study populations and design that influence interpretation. We focus on populations at high risk of HCV transmission and acquisition, including people who inject drugs and HIV-positive men who have sex with men, and highlight the potential effects of diagnosis and treatment of acute HCV infection in contributing to HCV elimination.
Similar articles
-
Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S238-S244. doi: 10.1093/cid/ciad344. Clin Infect Dis. 2023. PMID: 37579203 Review.
-
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.Dig Liver Dis. 2018 Feb;50(2):113-123. doi: 10.1016/j.dld.2017.11.013. Epub 2017 Nov 27. Dig Liver Dis. 2018. PMID: 29233687 Review.
-
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.Lancet Gastroenterol Hepatol. 2017 May;2(5):347-353. doi: 10.1016/S2468-1253(17)30003-1. Epub 2017 Mar 1. Lancet Gastroenterol Hepatol. 2017. PMID: 28397698 Clinical Trial.
-
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.Nephrology (Carlton). 2018 May;23(5):446-452. doi: 10.1111/nep.13050. Nephrology (Carlton). 2018. PMID: 28339162
-
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.Lancet Infect Dis. 2017 Feb;17(2):215-222. doi: 10.1016/S1473-3099(16)30408-X. Epub 2016 Oct 28. Lancet Infect Dis. 2017. PMID: 28029529 Clinical Trial.
Cited by
-
Nanoparticles and Antiviral Vaccines.Vaccines (Basel). 2023 Dec 27;12(1):30. doi: 10.3390/vaccines12010030. Vaccines (Basel). 2023. PMID: 38250843 Free PMC article. Review.
-
HCV RNA Quantification by a Domestic Commercial Assay: A Case Study among People Who Inject Drugs in Vietnam.Diagnostics (Basel). 2023 Nov 16;13(22):3456. doi: 10.3390/diagnostics13223456. Diagnostics (Basel). 2023. PMID: 37998592 Free PMC article.
-
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.JHEP Rep. 2023 Jul 27;5(10):100867. doi: 10.1016/j.jhepr.2023.100867. eCollection 2023 Oct. JHEP Rep. 2023. PMID: 37771545 Free PMC article.
-
Reinfection incidence and risk among people treated for recent hepatitis C virus infection.AIDS. 2023 Oct 1;37(12):1883-1890. doi: 10.1097/QAD.0000000000003651. Epub 2023 Jul 17. AIDS. 2023. PMID: 37467042
-
Gastrointestinal tract and viral pathogens.World J Virol. 2023 Jun 25;12(3):136-150. doi: 10.5501/wjv.v12.i3.136. World J Virol. 2023. PMID: 37396706 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical